Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
15.64
+0.13 (0.81%)
May 1, 2025, 4:00 PM EDT - Market closed
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Teva Pharmaceutical stock have an average target of 24, with a low estimate of 18 and a high estimate of 30. The average target predicts an increase of 53.50% from the current stock price of 15.64.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 6, 2025.
Analyst Ratings
The average analyst rating for Teva Pharmaceutical stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $23 → $20 | Strong Buy | Maintains | $23 → $20 | +27.92% | Mar 6, 2025 |
| UBS | UBS | Strong Buy Maintains $30 → $27 | Strong Buy | Maintains | $30 → $27 | +72.69% | Jan 30, 2025 |
| Barclays | Barclays | Buy Maintains $28 → $26 | Buy | Maintains | $28 → $26 | +66.29% | Jan 30, 2025 |
| UBS | UBS | Strong Buy Maintains $28 → $30 | Strong Buy | Maintains | $28 → $30 | +91.88% | Jan 23, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $23 → $30 | Buy | Maintains | $23 → $30 | +91.88% | Jan 17, 2025 |
Financial Forecast
Revenue This Year
17.59B
from 16.54B
Increased by 6.30%
Revenue Next Year
17.51B
from 17.59B
Decreased by -0.43%
EPS This Year
2.60
from -1.45
EPS Next Year
2.67
from 2.60
Increased by 2.52%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 18.2B | 18.3B | 18.9B |
| Avg | 17.6B | 17.5B | 17.9B |
| Low | 16.7B | 16.6B | 16.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 10.2% | 4.1% | 8.0% |
| Avg | 6.3% | -0.4% | 2.0% |
| Low | 1.2% | -5.7% | -6.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.71 | 2.92 | 3.31 |
| Avg | 2.60 | 2.67 | 2.97 |
| Low | 2.45 | 2.45 | 2.71 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 12.1% | 24.1% |
| Avg | - | 2.5% | 11.3% |
| Low | - | -5.9% | 1.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.